File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Population-based treatment results of hepatoblastoma in children of Hong Kong

TitlePopulation-based treatment results of hepatoblastoma in children of Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 109, abstract no. P-0235 How to Cite?
AbstractPURPOSE/OBJECTIVE: The five hospitals of Hong Kong forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) established a uniform treatment protocol for hepatoblastoma (HB) since 1996 comprising of primary surgical resection for resectable tumour or in most instances, neoadjuvant chemotherapy (cisplatinum, 5-fluorouracil and vincristine or alternative regimen of cisplatinum and doxorubicin) followed by complete surgical resection of tumour. We reviewed the population-based treatment results of HB in Hong Kong. MATERIALS AND METHODS: The clinical data of all cases diagnosed between 1-Jun-1996 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. Each case was assigned as standard risk (SR) or high risk (HR) according to the following criteria, HR: presence of either AFP < ? 100 ng/ml or unresectable tumour or tumour rupture or distant metastases or portal vein thrombosis; SR: resectable tumour without the HR features. RESULTS: During the study period, a total of 51 cases of HB including 35 SR and 16 HR cases were diagnosed. Twenty-eight (55%) were males. The median ages of the whole group, SR and HR were 1.2 years (range, 0.1 to 14.6 years), 1.0 year (0.1 to 14.6 years) and 1.2 years (0.3 to 11.3 years), respectively. The median follow up duration was 3.7 years (range, 0.0 to 15.8 years). The 5-year event-free survival (EFS) and overall survival (S) of the whole group were 74.5% and 79.9%, respectively. The 5-year EFS and S of the SR cases were 93.4% and 100% whilst those of the HR cases were 36.5% and 41.7%, respectively (p < 0.0001 for SR v HR). CONCLUSIONS: The treatment results of the SR HB are significantly better than those of the HR cases. Future goals may aim at reducing the chemotherapy for the SR cases and improving the survival of the HR cases.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Liver tumours: abstract no. P-0235
Persistent Identifierhttp://hdl.handle.net/10722/193629
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorChiang, AKen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorLi, Cen_US
dc.contributor.authorYuen, Hen_US
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLi, CBen_US
dc.date.accessioned2014-01-20T05:11:34Z-
dc.date.available2014-01-20T05:11:34Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 109, abstract no. P-0235en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193629-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Liver tumours: abstract no. P-0235-
dc.description.abstractPURPOSE/OBJECTIVE: The five hospitals of Hong Kong forming the Hong Kong Paediatric Haematology and Oncology Study Group (HKPHOSG) established a uniform treatment protocol for hepatoblastoma (HB) since 1996 comprising of primary surgical resection for resectable tumour or in most instances, neoadjuvant chemotherapy (cisplatinum, 5-fluorouracil and vincristine or alternative regimen of cisplatinum and doxorubicin) followed by complete surgical resection of tumour. We reviewed the population-based treatment results of HB in Hong Kong. MATERIALS AND METHODS: The clinical data of all cases diagnosed between 1-Jun-1996 and 31-Dec-2011 were reviewed up to the date of 31-Dec-2012. Each case was assigned as standard risk (SR) or high risk (HR) according to the following criteria, HR: presence of either AFP < ? 100 ng/ml or unresectable tumour or tumour rupture or distant metastases or portal vein thrombosis; SR: resectable tumour without the HR features. RESULTS: During the study period, a total of 51 cases of HB including 35 SR and 16 HR cases were diagnosed. Twenty-eight (55%) were males. The median ages of the whole group, SR and HR were 1.2 years (range, 0.1 to 14.6 years), 1.0 year (0.1 to 14.6 years) and 1.2 years (0.3 to 11.3 years), respectively. The median follow up duration was 3.7 years (range, 0.0 to 15.8 years). The 5-year event-free survival (EFS) and overall survival (S) of the whole group were 74.5% and 79.9%, respectively. The 5-year EFS and S of the SR cases were 93.4% and 100% whilst those of the HR cases were 36.5% and 41.7%, respectively (p < 0.0001 for SR v HR). CONCLUSIONS: The treatment results of the SR HB are significantly better than those of the HR cases. Future goals may aim at reducing the chemotherapy for the SR cases and improving the survival of the HR cases.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titlePopulation-based treatment results of hepatoblastoma in children of Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailChiang, AK: chiangak@hku.hken_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.emailLi, CB: jamesli@hku.hken_US
dc.identifier.authorityChiang, AK=rp00403en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227218en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage109-
dc.identifier.epage109-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats